Drug Approval Process

My tests had several questions that referenced to the drug approval process. I suggest that anyone planning to take the MPJE for any state be familiar with the drug approval processes

Investigational New Drug Application

•1stapplication before drug is given to humans

•Federal Drug Administration (FDA) has 30 days to decide if suitable for testing

•Must provide clinical protocols to be used in human testing

Clinical Trials

Initiated after FDA approves the investigational new drug application

3 phases before marketing and 1 phase after marketing

Phase 1: Small group of healthy individuals to evaluate toxicity, kinetics, safety

Phase 2: Large group (100+) with the disease being treated to evaluate effectiveness, safety, and adverse drug events (ADEs)

Phase 3: Large group (1000+) to evaluate effectiveness, double-blinded with placebo

Phase 4: Post-marketing surveillance to determine if drug should stay on the market

New Drug Application (NDA)

Can apply once data on safety, efficacy, toxicity, stability, production methods, packaging and clinical trial data exists

Typically takes 6 months for review 

Abbreviated New Drug Application (ANDA)

For introducing a generic of an already approved drug

Requires proof of kinetics, bioequivalence/bioavailability

Supplemental New Drug Application (SNDA)

For changes to synthesis, production, manufacturer location, packaging and/or labeling

For new dose form, strength or therapeutic use

Controlled Substances CIII-CV

When taking the exam it’s important to read each question carefully and concentrate on which law, general concept or principle the question is testing.

When a drug name is given in a question, identify if it is OTC, prescription only or a controlled substance. Then, use that information to determine which laws apply and how they apply to the question at hand.

Always remember, state law may be stricter and if so STATE LAW APPLIES.

CIII Medications

Drugs with Moderate to Low Potential for Physical and Psychological Dependence

Combination products containing less than 90mg of codeine per dosage unit (Tylenol with codeine)

Fiorinal is CIII however Fioricet is non-controlled

  Fiorinal: ASA 325mg/butalbital 50mg/caffeine 40mg

  Fioricet: APAP 325mg/butalbital 50mg/caffeine 40mg

buprenorphine (Suboxone)benzphetamine (Didrex)
ketaminephendimetrazine
anabolic steroidsThiopental
testosteroneFiorinal
CIII medications

CIV Medications

Drugs with Low Potential for Abuse or Dependence
alprazolam (Xanax)diazepam (Valium)
carisoprodol (Soma)lorazepam (Ativan)
clonazepam (Klonopin)midazolam (Versed)
clorazepate (Tranxene)temazepam (Restoril)
triazolam (Halcion)phenobarbital
butorphanol
CIV Medications

CV Medications

Drugs with Lower Potential for Abuse 

Preparations containing limited quantities of certain narcotics

Generally used for antidiarrheals, antitussives, and analgesic purposes

Examples: Cough preparations with ≤ 200mg of codeine per 100mL or 100g (Robitussin AC, Phenergan with Codeine), Lomotil, Lyrica

CIII-CV Valid Types of Prescriptions

Written signed prescription

Fax of written prescription

Erx

Verbal

Containing all information except prescriber signature

Transfer

ONE TIME for the purpose of REFILL dispensing

Pharmacies electronically sharing a real-time system may transfer up to max refills permitted by law and prescription

CIII-CIV Refills (and CV in Most States)

No more than 5 refills within a 6 month period

Must keep information on the back of the original prescription or in a computerized record-keeping system

Must be accessible within 48 hours

Must record: Prescriber name, Name and address of the patient, Quantity dispensed on each refill, Date of dispensing for each refill, Name or ID code of the dispensing pharmacist and Number of the original prescription order

CIII-CV Partial Filling

Partial filling is allowed

Each partial should be recorded in the same manner as a refill

The total quantity dispensed in all partial fillings cannot exceed the total quantity prescribed

No dispensing may occur beyond 6 months after the date Rx was written

Filling a CV Without a Prescription/Limitations

Only a pharmacist may dispense an over the counter CV

A non-pharmacist may complete the money transfer at the register

Purchaser must be ≥ 18 years old (Rph can require proof of age)

Furnish identification 

Bound record book must be maintained by the pharmacist: Name and address of the purchaser, Name and quantity of the CV purchased, Date of purchase, Name or initials of pharmacist that dispensed, Records must be kept for 2 years

Not more than _______ in a 48 hourperiod to the same purchaser

240mL (8 ounces) of any controlled substance containing opium

48 dosage units of any such controlled substance containing opium

120mL (4 ounces) of any other controlled substance

24 dosage units of any other controlled substance

Therefore, MAX is 4 fluid ounces of codeine containing cough syrup over the counter to a given purchaser in a 48 hour period.

Check out the detailed information in our guided course and downloadable study guides on Teachable.

Controlled Substances CII

When taking the exam it’s important to read each question carefully and concentrate on which law, general concept or principle the question is testing.  

When a drug name is given in the question identify if it is OTC, prescription only or a controlled substance. Use that information to determine which laws apply and how they apply to the question at hand.

Always remember, state law may be stricter and if so STATE LAW APPLIES.

Drugs with a high potential for abuse
Potential to lead to severe psychological or physical dependence
Dangerous
hydromorphone (Dilaudid) fentanyl (Sublimaze, Duragesic)hydrocodoneamobarbital
methadone (Dolophine)morphineamphetamine (Dexedrine, Adderall)glutethimide
meperidine (Demerol)opiummethamphetamine (Desoxyn)pentobarbital 
oxycodone (OxyContin, Percocetcodeinemethylphenidate (Ritalin)secobarbital
CII Controlled Substances

Barbiturates

Amobarbital (Amytal), pentobarbital (Nembutal) and secobarbital (Seconal) are CIIs.

Phenobarbital (Luminal) is a CIV.

Hydrocodone

Hydrocodone was reclassified to CII in 2014.

CII Prescription Requirements: Valid Types of Prescriptions

Written signed prescription

Erx

Oral (ONLY in emergency)

Fax (ONLY if home infusion, long term care facility, hospice)

CII Prescriptions: What Can be Changed?

Patient address (can also obtain from patient)

Drug strength

Dosage form

Drug quantity

Directions

CII Prescriptions: What Cannot be Changed?

Patient’s Name

Controlled substance prescribed

Prescriber’s Signature

⬆️ Any of the above items would require a new prescription.

CII Prescriptions: Partial Filling

No refills are allowed on CII prescriptions

Partial may be dispensed: 

*If it is not prohibited by State laws*

The partial fill is requested by the patient or the practitioner who wrote the prescription.

The total quantity dispensed in all partial fillings does not exceed the total quantity prescribed.

Within 30 days of the date on which the prescription was written 

Exception: Terminal patients may get a partial dispense and prescription is void 60 days after written

Partial dispense prescription documentation:

Date of partial fill

Quantity dispensed

Remaining quantity

Dispensing pharmacist

Check out the detailed information in our guided course and downloadable study guides on Teachable!!

DEA Form 106: Theft or Loss of Controlled Substances

Discovering a Theft of Controlled Substances

Must contact the nearest DEA Diversion Field Office upon discovery

Notify local police

Complete DEA Form 106 Report of Theft or Loss of Controlled Substances 

If review shows no actual controlled substance loss, then Form 106 is not needed.  Inform DEA in writing to close the initial report. 

Link to PDF of DEA Form 106: https://www.deadiversion.usdoj.gov/21cfr_reports/theft/DEA_Form_106.pdf

Federal Investigation of Pharmaceutical Theft or Robbery

A Federal Investigation occurs if any one or more of the following:

Replacement cost of controlled substances is ≥ $500

Someone is killed or suffers significant injury

Interstate or foreign commerce is involved in planning or executing the crime  

In-transit Loss

If an in-transit loss occurs, the supplier is responsible for reporting the loss.  

The pharmacy is only responsible after signing for the shipment.

Pharmacy Employment Practices

Pharmacy must not employ anyone with a controlled substance felony on record or anyone who has had a DEA registration denied, revoked or suspended.

A waiver may be approved in certain situations but will only be considered for approval if diversion is unlikely to occur.

DEA Form 41: Destruction of Controlled Substances

Two Methods:

1. Request DEA authorization to destroy damaged, outdated, and/or unwanted controlled substances 

Once per calendar year for retail pharmacies through the nearest DEA Division Field Office

Complete DEA Form 41 (Registrant’s Inventory of Drugs Surrendered)

Write a letter to the DEA to request permission to destroy, including: date and method of destruction, names of 2 people who will be witnesses (physician, pharmacist, physician assistant, nurse practitioner, nurse or law enforcement officer)

Send letter and DEA Form 41 at least 2 weeks prior to proposed destruction date and await written decision

Once destroyed, signed and completed copies of DEA Form 41 must be forwarded to the DEA

Exception to prior authorization: If a member of a state law enforcement authority or regulatory agency witnesses the destruction, then prior authorization from the nearest DEA Diversion Field Office or local DEA Special Agent in Charge is not required

Copies of a DEA Form 41 or state controlled substance destruction form must be forwarded to the local DEA Diversion Field Office after the destruction

2. Forward controlled substances to a DEA registered distributor who handles the disposal of drugs

Can be done at anytime

Local DEA Division Field Office can provide an updated list of distributors

The distributor must issue a DEA Form 222 to the pharmacy if CII medications are included

For CIII-CV, the pharmacy should document drug name, dose form, strength, quantity and date transferred in writing 

The DEA registered distributor who will destroy the controlled substances is then responsible for submitting DEA Form 41 to the local DEA Diversion Office

Hospital/Institution Pharmacy Controlled Substances

Must keep records of dispensing, destruction, disposal including:

Patient name with date of birth or medical record number as second identifier

Drug name, dose and dose form

Prescriber

Name of individual that dispenses

Name of individual that administers

Date and time of administration

Name of witness observing disposal of unused drug 

“Blanket Authorization”

Issued on a very limited basis for registrants associated with hospitals, clinics or others needing to dispose of used needles, syringes and other injectable objects only

Granted due to the contamination by hazardous body fluids

Requests for ”blanket authorization” are based on: 

Frequency of destruction and volume involved

Method of destruction – must be incinerated or other method involving complete destruction

Registrant’s history 

Security at the pharmacy or registered location

Name and title of the person responsible for destruction

Must still complete a DEA Form 41

Source: deadiversion.usdoj.gov

Link to DEA Form 41: https://www.deadiversion.usdoj.gov/21cfr_reports/surrend/41_form.pdf

DEA 222 Forms: Triplicate, Single-Form, CSOS, Returns and Transfers

DEA 222 Triplicate Forms

Used to purchase, transfer or return schedule I and II medications

Can be signed by the individual authorized on the application for registration or anyone else with power of attorney

Have original, duplicate and triplicate carbon sheets

Copy #ColorWhere does it go?
1BrownSupplier
2GreenTo supplier then to DEA
3BlueKept by purchaser
Triplicate Form Copies and Records

Each different product must be on a separate line! 

Link to example of filling out DEA 222 triplicate form: https://northamerica.covetrus.com/docs/default-source/regulatory-documents/222-checlist-v16.pdf?sfvrsn=e8e26e73_2

An order may be partially filled within 60 days (expires at 60 days).

Purchaser notes the quantity recieved and date on Blue Copy 3 when receiving their order.

For Federal DEA purposes these records need to be kept for 2 years (some states may require longer).

Any unused forms must be returned to the DEA.

Lost or stolen forms should be reported to the Special Agent in Charge of the DEA in the Divisional office responsible for the area.

For reverse distributors, using the triplicate form process, pharmacy would receive Copy 1 and Copy 2 of the triplicate form, keeping Copy 1 and mailing Copy 2 to the local DEA office. 

DEA Legal Amendment to Update to a Single-Sheet Format for DEA 222

SUMMARY: The Drug Enforcement Administration (DEA) is amending its regulations to implement a new single-sheet format for DEA Form 222, used by DEA registrants to order schedules I and II controlled substances. The rule provides for a two-year transition period, during which the existing triplicate version of the forms may continue to be used. The rule also includes a number of minor procedural changes.

DATES: This rule is effective October 30, 2019.

Link to the detailed DEA Single-Sheet Format document: https://www.deadiversion.usdoj.gov/fed_regs/rules/2019/fr0930.htm

Any triplicate forms on hand may be used until October 30, 2021.  

Once triplicate forms on hand have been used, the DEA will begin sending single sheet DEA 222 Forms instead of the triplicate forms.  

If any triplicate forms are still on hand on October 30, 2021, they should be sent into the Registration Section at DEA Headquarters and the single-sheet form should begin being used.  

Since there is no longer a triplicate portion to keep at the pharmacy, the pharmacy will need to make a copy of the new single-sheet DEA 222 form either as a hard copy or electronic copy.  Pharmacy will still need to document the quantity received and the date received at the pharmacy. 

For Federal DEA purposes these records need to be kept for 2 years (some states may require longer).   

The DEA 222 process has also been updated for reverse distributors.  With the triplicate form process, pharmacy would receive Copy 1 and Copy 2 of the triplicate form, keeping Copy 1 and mailing Copy 2 to the local DEA office.  With the single-sheet DEA 222 Form, pharmacy will receive the single copy, then make a copy and send it to the local DEA office.  It is still required to document the quantity shipped and date shipped on the order form.

CSOS: Controlled Substance Ordering System

CSOS is the computerized system used for ordering controlled substances. 

CSOS orders can include scheduled I-V and non-controlled.

If CSOS is down or the CSOS account is closed, then a paper form will be required to order.  

Ordering overview diagram
Source: DEA website

1. An individual enrolls with DEA and, once approved, is issued a personal CSOS Certificate.

2. The purchaser creates an electronic 222 order using an approved ordering software. The order is digitally signed using the purchaser’s personal CSOS Certificate and then transmitted to the suppliers. The paper 222 is not required for electronic ordering.

3. The supplier receives the purchase order and verifies that the purchaser’s certificate is valid with DEA. Additionally, the supplier validates the electronic order information just like it would a paper order.

4. The supplier completes the order and ships to the purchaser. Any communications regarding the order are sent electronically.

5. The order is reported by the supplier to DEA within two business days

Above graphic and list is provided from the DEAecom.gov website.

Link to CSOS overview: https://www.deaecom.gov/overview.pdf

Distribution of Controlled Substances

Distribution shall be recorded by distributing and receiving pharmacies or practitioners. Receipts are to include: the controlled substance name, dosage form, dosage units in each container and number of containers ordered and received for record keeping.

If the controlled substance is a Schedule I or II, a DEA 222 must be used for the transaction.

Total number distributed during the calendar year shall not exceed 5% of the total number of all controlled substances during the same calendar year.

If number distributed will exceed 5% must obtain a registration to distribute controlled substances (i.e., wholesaler’s permit).

A PRESCRIBER MAY NOT WRITE A PRESCRIPTION FOR “OFFICE USE”.

Next week we will review DEA Form 41.

DEA Registration Applications: What should a Pharmacist know for the MPJE?

Part 1 of our deep dive into DEA Applications and Forms

What is the DEA?

Drug Enforcement Administration

Part of the United States Department of Justice

Responsible for the Controlled Substances Act

Those authorized to possess controlled substances must be registered by the DEA. 

Each location that manufacturers, distributes or dispenses controlled substances must have its own DEA registration.

Pharmacists usually do not need to register as an individual with the DEA if they are working in a registered location.  

Form 224Application for Pharmacy registration
Form 224aRenewal for Pharmacy registration
Form 225Application for Manufacturer or Researcher registration
Form 225aRenewal for Manufacturer or Researcher registration
Table of DEA Application Forms

Examples of applications can be found at:

https://www.deadiversion.usdoj.gov/drugreg/reg_apps/index.html

All locations that manufacturer, distribute or dispense controlled substances must register with the DEA with the exception of:

  1. Warehouses used for storage of controlled substance by registrants
  2. A prescriber’s office where controlled substances are prescribed – not administered or dispensed.
  3. Freight delivery companies
  4. A location where sales of controlled substances are made, solicited or supervised, but the location does not actually keep controlled substances on site

DEA registrations are valid for 36 months.

Renewal forms are sent to the registrant 60 days before the current registration expires.

Registrant must contact the DEA in writing if they do not receive their renewal forms within 45 days before the current registration expires.

The DEA may deny or revoke a registration if:

  1. Information on the application is untrue
  2. Applicant has been convicted of a drug-related felony
  3. Registration would be inconsistent with the public interest
  4. State license has been suspended, revoked or denied

May also revoke license if applicant is excluded from Medicare or state health program participation

Federal law does NOT require the applicant for DEA registration to be a pharmacist. 

Hospital registrations are treated as an “institutional practitioner” and DEA registration is issued to the entire hospital.

Power of Attorney

An applicant may authorize another individual or individuals to sign official forms by filing with the Registration Unit of the DEA, a Power of Attorney for each authorized individual. It remains valid until revoked with a Notice of Revocation.

Source: deadiversion.usdoj.gov

Next weeks deep dive will review DEA Form 222.

DEA Applications and Forms

The DEA applications, renewals and forms were on every MPJE I have taken in one way or another.

Over the next several weeks we will do a deeper dive into each type of application and renewal or form to learn the details.

Basics

What is the DEA?

Stands for Drug Enforcement Administration

Part of the United States Department of Justice

Responsible for the Controlled Substances Act

Those who are authorized to possess controlled substances must be registered by the DEA. 

Pharmacists typically do not need to register individually with the DEA if they are working in a registered organization.  

Adulterated and Misbranded – What is the Difference?

ADULTERATED medications have an issue related to the COMPOSITION.

MISBRANDED medications have an issue with the LABELING.

Adulterated:

Contains any substance that is decomposing, filthy or putrid

Manufactured, packaged or stored in unsanitary conditions that may have caused contamination

Not manufactured under Good Manufacturing Practices (GMPs)

Contains a color additive that is unapproved

Contains a drug whose strength, purity or quality is lower than the official standards in the compendia

Contains a drug whose strength, purity or quality is lower than listed on the label

Container is made of a substance that leaches into the product

Contains any other ingredient as a substitute for the active drug listed

Misbranded:

Label has incorrect information or is misleading

Label does not list the name and location of the manufacturer, packer or distributor

Label does not contain a statement, word or any other information that is required by law

Label does not list the established name of the active drug

Label does not list each active drug ingredient

Label does not contain the “Rx Only” statement if the drug is only available by prescription (this is not required on the prescription label if dispensing to an outpatient consumer)

Label does not contain a precautionary statement for a medication that is at risk of deterioration

Label does not include the quantity of the container contents (such as count of 100, weight of 50g, or volume of 4 fl. oz.)

Non-prescription drug label does not contain adequate directions for use or appropriate warnings to protect consumers using the medication or packaging

Label is not in compliance with USP (US Pharmacopeia) and/or NF (National Formulary) specifications

Labeling offers one drug for sale under the name of a different drug

Pharmacy dispenses a prescription only medication without having a legal prescription or an authorized refill

Good Manufacturing Practices (GMPs)

Regulations that identify the minimum standards for manufacturing pharmaceuticals in the United States with the goal of safe and quality medications. Compliance is the responsibility of manufacturers. Manufacturers must be registered with the FDA, describe their manufacturing and production processes in their NDA (new drug application) process, and be inspected regularly. Inspections are typically every 2 years unless prior deficiencies warrant more frequent inspections.

Labeling

Labeling includes writing, print and/or graphics the immediate container of a medication and the outer container. If there is an outer container, labeling on the inner product must also appear on the outside container.

The package insert is considered part of the labeling.

The prescription label created by the pharmacist is also included in labeling.

What are grandfathered medications?

The Food Drug and Cosmetic Act of 1938

The Food Drug and Cosmetic Act of 1938 (FDCA) required medications be proven safe when used according to the directions on the label prior to marketing. It also required that labels include adequate directions for use. The Food Drug and Cosmetic Act of 1938 also requires habit-forming drugs to include a warning of the habit forming risk. Drugs already marketed prior to 1938 were exempt or “grandfathered” and did not require a change to their labeling or safety studies under this law. This was the first law that included cosmetics and medical devices into medication and food legislation. The FDCA also defined a dietary ingredient as “a vitamin, mineral, herb, or other botanical, amino acid, a dietary substance to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite, constituent, extract, or combination of any of the aforementioned ingredients”. The FDCA also established the Homeopathic Pharmacopoeia of the United States (HPUS) as an official compendium, requiring drug products using an official listed name to meet all of its standards (otherwise would be considered misbranded or adulterated). This Act became the groundwork for further amendments and subsequent laws regarding drug legislation in the United States. Other specifications in the FDCA include the medications below.

Ipecac Syrup

Reminder: Ipecac Fluid Extract is not the same as Ipecac Syrup. Ipecac Fluid Extract is 14 times as potent as Ipecac Syrup!

Must have a statement boxed and in red text that states “For emergency use to cause vomiting in poisoning. Before using, call physician, the poison prevention center, or hospital emergency room immediately for advice.”

Must carry the statement “Warning: Keep out of reach of children. Do not use in unconcious persons or for poisoning involving corrosives (lye, strong acids), petroleum distillates such as kerosine, gasoline, cleaning fluids, or for strychnine”.

The usual dosage is 1 Tbsp or 15mL in patients over one year of age.

Ipecac syrup is only able to be sold in 1 oz or 30mL containers.

The FDCA also requires that certain drugs and adjuvants carry special warning labels. Examples are:

FD&C Yellow No. 5 (tartrazine)

Labeling must list in the precautions and specify that it may cause allergic reactions in some individuals

Aspartame

Labeling must carry a warning of “Phenylketonurics: Contains phenylalanine _x_ mg per _x_ (dosage unit)”

Sulfites

Labeling must contain an allergy warning in the labeling of prescription drugs and wines

Mineral Oil

Labeling must contain a warning that it should be used at bedtime, warn that it not be used in infants unless under the direction of a physician and should discourage use in pregnant women

Wintergreen oil (methyl salicylate) in amounts > 5%

Labeling should warn to keep out of the reach of children and also warn that using other than how directed may be dangerous

Sodium phosphate (saline laxative)

Packaging is limited to no more than 90mL per OTC container

Isoproterenol Inhalation Products

Labeling should warn not to exceed the dose prescribed and also warn to get medical assistance and/or contact physician if user continues to have breathing difficulty

Acetophenetidin (Phenacetin)

Labeling must carry a warning about possible kidney damage when taken in large amounts or for long periods of time

Salicylates (includes aspirin)

Labeling must include a warning about Reye’s Syndrome

Alcohol warning

Labeling for analgesics and antipyretics (acetaminophen, aspirin, ibuprofen, naproxen, etc.) are required to warn patients to consult with their physician before taking these medications if they consume ≥ 3 alcoholic beverages per day